Together, these findings indicate that Sirts and Parps are involved in ALS and that any treatments that augment NAD+ availability should also investigate how elevating Sirt activity or reducing Parp activity may lead to further benefits. The gene discussed is PARP1; the disease is amyotrophic lateral sclerosis.